Journal of Cancer Science and Research
Open Access

Faculte de medecine, Universite Mohammed VI des Sciences de la Sante. Casablanca, Morocco

Biography

Wafaa Kaikani  has been involved in many quantitative as well as qualitative studies; but her expertise are mostly related to qualitative and action research. Faculte de medecine, Universite Mohammed VI des Sciences de la Sante. Casablanca, Morocco

Publications

• Research Article   
  Metastatic hormone-sensitive prostate cancer: A Systematic Review of the Value of Current Therapies
  Author(s): Wafaa Kaikani*, Mohammed sqalli Houssaini and Khalid Hadadi
  
  PROSTATE cancer (PC) is the second most frequent cancer in males. Based on GLOBOCAN 2018 estimates, 1,356,176 new cases of prostate cancer and a mortality of 378,553 are expected in 20201. Despite an overall 5-year survival rate of 98.2%, mHSPC has a dismal 30% 5-year survival rate2. Metastatic hormone-sensitive prostate cancer (mHSPC) is the disease space whereby men have metastatic prostate cancer and have never received (ie. are sensitive to) androgen deprivation therapy (ADT). mHSPC previously constituted ~30% of prostate cancer cases , however, from 2004-2012 secondary to PSA testing, the estimate was ~5% of cases in USA3. Many experts in the field suggest that with decreased PSA screening over the last few years, as a result of the United States Preventative Services Task Force (USPSTF) Grade D recommendation for PSA screening (subsequently upgraded to C 4), that these estimates.. View More»
  

  Abstract PDF